Oliver Mobasser

Mr. Mobasser’s representative experience includes advising: 

• GSK on a variety of matters, including: 
  • Its strategic global collaboration and licensing agreement with Alector for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s disease
  • Its global license and collaboration with SpringWorks Therapeutics, Inc. for development and commercialization of nirogacestat, SpringWorks’ investigational oral gamma secretase inhibitor, in combination with Blenrep (belantamab mafodotin-blmf), GSK’s antibody-drug conjugate targeting B-cell maturation antigen (BCMA) 
  • Various other early-stage clinical trial, collaboration, development, and supply arrangements 
  • The divestment of its Prevacid 24HR business to Perrigo Company 
  • The divestment of assets relating to the Bialcol and Cibalgina brands in Italy to Vemedia 
  • The divestment of five over-the-counter dermatology brands and one pediatric cough remedy brand to the STADA Group 
  • The divestment of four established over-the-counter brands in eight countries to Pharma SGP
• Swedish Orphan Biovitrum AB (publ) (Sobi™) on a variety of matters, including:
  • Its strategic licensing agreement with Selecta Biosciences for SEL-212, a phase-3 ready therapy for the treatment of chronic refractory gout, with a deal value of approximately US$730 million 
  • Its strategic licensing and collaboration agreement with Apellis Pharmaceuticals Inc. for co-development and exclusive ex-US commercialisation rights for systemic pegcetacoplan
• Norgine, a Netherlands-based specialty pharmaceutical company, in its US$2 billion sale to Goldman Sachs
• Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, in connection with its its licensing agreement with ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies for women’s health, to commercialise and launch Linzagolix, an oral GnRH antagonist 
• Astorg and OPEN Health, on data protection matters related to the acquisition of The CM Group, an integrated commercialization platform 
• Lindsay Goldberg, on data protection matters related to its investment in MMS Holdings Inc., a leading data-focused contract research organization
• Leadiant Biosciences on the sale of all of its assets relating to Revcovi, a pharmaceutical product for the treatment of a rare immunodeficiency disease, to Chiesi Farmaceutici
• Novo Holdings A/S on its acquisition of BBI Group, a leading supplier of products and services to the global diagnostics and life sciences industries
• A consortium consisting of Astorg Asset Management, Nordic Capital, Novo Holdings and their portfolio company eResearchTechnologies on the data privacy aspects of its merger with Bioclinica, a technological and scientific leader in clinical imaging
• Frontier Medicines, Corp. on the data privacy aspects of its global partnership with AbbVie to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein target
• Acino Pharma in relation to its purchase of a portfolio of over-the-counter and prescription pharmaceutical products in the Near East, Middle East and Africa, for a total value in excess of US$200 million 
• Oasmia Pharmaceutical AB on its global strategic partnership for the development and commercialization of its proprietary anticancer product Apealea with Elevar Therapeutics, with a deal value of approximately USD$698 million 
• Ligand Pharmaceuticals on its sale of Vernalis (R&D) Limited, a UK-based fragment and structure-based drug discovery research company, to HitGen
• Permira, on contracts, regulatory and IP matters related the joint acquisition and combination of Kedrion Biopharma and Bio Products Laboratory, two leading providers of medicinal products derived from human blood plasma
• Permira on data protection, contracts, regulatory and IP matters related to the acquisition of Quotient Sciences, a provider of CDMO and CRO services to pharma and biotech companies 
• Quotient Sciences on its acquisition of Arcinova, the UK based multiservice contract development and manufacturing organization 
• BC Partners on IP, contracts, data protection and regulatory matters related to the acquisition of a majority interest in Synthon International Holding B.V., a global market leader in the development of complex generics 
• Various pharmaceutical and medical technology companies on agreements for the conduct of clinical trials in the EU, including GDPR compliance aspects of such trials

*Matter handled prior to joining Latham & Watkins